Polymeric hollow nanocapsules have attracted significant research attention as novel drug carriers and their preparation is of particular concern owing to the feasibility to encapsulate a broad range of drug molecules. This work presents for the first time the synthesis and development of novel poly-N-acryloyl l-phenylalanine methyl ester hollow core nanocapsules (NAPA-HPNs) of avg. size ca. 100-150 nm by the mini-emulsion technique. NAPA-HPNs are biocompatible and capable of encapsulating sodium nitroprusside (SNP) at a rate of ∼1.3 μM per mg of capsules. These NAPA-HPNs + SNP nano-formulations maintained homeostasis of macrophages which carry and facilitate the action of various drug molecules used against various diseases. These NAPA-HPNs also facilitate the prolonged release of a low level of nitric oxide (NO) and enhance the metabolic activities of pro-inflammatory macrophages, which are important for the action of various drugs in body fluids. NAPA-HPN mediated skewing of naïve macrophages toward the M1 phenotype potentially demonstrates its adjuvant action on the innate immune system. These results potentially suggested that NAPA-HPNs can serve both as a carrier of drugs as well as an adjuvant for the immune system. Thus, these nanocapsules could be used for the effective management of various infectious or tumor diseases where immune-stimulation is paramount for treatment.
|Number of pages||9|
|State||Published - 28 Sep 2017|
Bibliographical noteFunding Information:
The work was supported by DST Fast-Track Grant for Young Scientists (Ref. SR/FTP/ETA-0079/2011) and UoH Start-up Grant (Ref. UH/F&A/2011-12/SG) to PP and Ramanujan Research Grant (SR/S2/RJN/03/2012) to HP from the Department of Science and Technology, New Delhi, India. VN was supported by a research grant from the DRDO (LSRB-271/SG&DD/2015).
© The Royal Society of Chemistry 2017.